SCHEMBL1899018

SCHEMBL1899018

O=C(O)c1cc(-c2ccccc2)nc2c(Cl)cc(Cl)cc12

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.64
HSD17B10 Q99714 3/20 0.59
HIF1A Q16665 2/20 0.59
ALDH1A1 P00352 2/20 0.59
PTGES O14684 1/20 0.59
ALOX5 P09917 1/20 0.59
CYP2C9 P11712 1/20 0.59
HPGD P15428 1/20 0.59
CASP7 P55210 1/20 0.59
DHODH Q02127 7/20 0.58
PDE10A Q9Y233 2/20 0.57
KDM4E B2RXH2 2/20 0.57
LMNA P02545 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
TP53 P04637 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C19 P33261 1/20 0.55
CTRC Q99895 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8619775 0.86 PPARA (0.64) PPARAHSD17B10HIF1AALDH1A1PTGES
SCHEMBL14895174 0.85 PPARA (0.48) PPARAHSD17B10HIF1AALDH1A1PTGES
SCHEMBL9788759 0.84 KMO (0.48) PPARAHSD17B10HIF1AALDH1A1PTGES
SCHEMBL8619739 0.84 PPARA (0.69) PPARAHSD17B10HIF1ADHODHPDE10A
SCHEMBL10390581 0.81 FABP4 (0.48) PPARAHSD17B10HIF1AALDH1A1PTGES
SCHEMBL1898306 0.79 HSD17B10 (0.86) HSD17B10HIF1AALDH1A1PTGESALOX5
SCHEMBL10390764 0.79 FABP4 (0.47) PPARAHSD17B10HIF1AALDH1A1PTGES
SCHEMBL22471917 0.78 KDM4E (0.59) PPARAHSD17B10HIF1AALDH1A1PTGES
SCHEMBL17211711 0.78 PPARA (1.00) PPARAHSD17B10ALDH1A1DHODHPDE10A
SCHEMBL16832437 0.77 GPR35 (0.49) HSD17B10HIF1AALDH1A1PTGESALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 EP disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B PPARA 2010/4885HSD17B10 3117/4885HIF1A 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.